PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19668418-3	2008	Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window.	voclosporin	0-11	calcineurin binding protein 1	Homo sapiens	41-62
24330024-0	2014	Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.	voclosporin	66-77	ATP binding cassette subfamily B member 1	Homo sapiens	23-37
24330024-2	2014	Pharmacokinetic drug interactions between voclosporin and a CYP3A inhibitor, inducer and substrate and a P-glycoprotein inhibitor and substrate were evaluated.	voclosporin	42-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65
24330024-6	2014	CONCLUSIONS: Administration of voclosporin concomitantly with strong inhibitors and inducers of CYP3A resulted in increased and decreased exposures, respectively, and should be considered contraindicated.	voclosporin	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-101
24330024-8	2014	Administration of voclosporin concomitantly with inhibitors and substrates of P-glycoprotein resulted in increased voclosporin and substrate exposures, respectively.	voclosporin	18-29	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
24330024-8	2014	Administration of voclosporin concomitantly with inhibitors and substrates of P-glycoprotein resulted in increased voclosporin and substrate exposures, respectively.	voclosporin	115-126	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
24392311-5	2013	Potential improvements to the calcineurin inhibitor class include a prolonged release tacrolimus formulation and voclosporin, a cyclosporine analog.	voclosporin	113-124	calcineurin binding protein 1	Homo sapiens	30-51
21966207-0	2011	Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.	voclosporin	5-16	calcineurin binding protein 1	Homo sapiens	24-45
18815080-0	2008	Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood.	voclosporin	107-118	calcineurin binding protein 1	Homo sapiens	84-105
16488299-2	2006	OBJECTIVE: Evaluate the safety and efficacy of ISA247, a new oral calcineurin inhibitor, in plaque psoriasis patients.	voclosporin	47-53	calcineurin binding protein 1	Homo sapiens	66-87
33971155-0	2021	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.	voclosporin	23-34	aurora kinase B	Homo sapiens	71-79
34284043-4	2021	In January 2021 the U.S. Food and Drug Administration (FDA) has approved voclosporin, a novel calcineurin inhibitor for the treatment of adult patients with active lupus nephritis.	voclosporin	73-84	calcineurin binding protein 1	Homo sapiens	94-115
34463434-0	2021	Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.	voclosporin	37-48	aurora kinase B	Homo sapiens	85-93
34392746-0	2021	Voclosporin: a novel calcineurin inhibitor for the managment of lupus nephritis.	voclosporin	0-11	calcineurin binding protein 1	Homo sapiens	21-42
34211153-0	2021	AURORA 1 reports efficacy of voclosporin in lupus nephritis.	voclosporin	29-40	aurora kinase B	Homo sapiens	0-8
34392746-3	2021	AREAS COVERED: : In this review, we approach the current state of LN management, the unmet therapeutic needs, and deep dive into voclosporin, a novel calcineurin inhibitor (CNI) that has demonstrated improved efficacy when added to a mycophenolate mofetil (MMF) and glucocorticoid regimen, without an increase in adverse events.	voclosporin	129-140	calcineurin binding protein 1	Homo sapiens	150-171
35249969-4	2022	The AURORA 1 trial demonstrated that voclosporin, a second-generation calcineurin inhibitor, effectively lowers proteinuria in patients with lupus nephritis, when added to mycophenolate mofetil with a better safety profile, compared with other calcineurin inhibitors.	voclosporin	37-48	calcineurin binding protein 1	Homo sapiens	70-91
33186226-4	2021	The AURORA trial reported positive results for the calcineurin inhibitor voclosporin as an oral add-on therapy to low dose steroids and MMF when given twice daily over a period of 52 weeks at an effect size of 18.5% for a CRR.	voclosporin	73-84	calcineurin binding protein 1	Homo sapiens	51-72
35168373-0	2022	Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis.	voclosporin	0-11	calcineurin binding protein 1	Homo sapiens	21-42
35168373-1	2022	OBJECTIVE: To describe the safety, efficacy, and potential role in therapy of voclosporin, an oral calcineurin inhibitor approved by the Food and Drug Administration (FDA) in January 2021 as an adjunct treatment for lupus nephritis.	voclosporin	78-89	calcineurin binding protein 1	Homo sapiens	99-120
35168373-10	2022	RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Voclosporin may be a favorable calcineurin inhibitor in patients with lupus nephritis, due to a predictable pharmacokinetic profile.	voclosporin	49-60	calcineurin binding protein 1	Homo sapiens	80-101
33394604-6	2021	In combination with mycophenolate mofetil, a B-cell-targeted therapy (belimumab) and an calcineurin inhibitor (voclosporin) have shown efficacy in recent lupus nephritis trials.	voclosporin	111-122	calcineurin binding protein 1	Homo sapiens	88-109
32721249-1	2020	Objective: The purpose of this study was to evaluate the potential of voclosporin (VOS) in preventing goblet cell (GC) loss and modulating interferon-gamma (IFN-gamma) producing CD4+ T cells in the mouse desiccating stress (DS) dry eye model.	voclosporin	70-81	interferon gamma	Mus musculus	139-155
32721249-1	2020	Objective: The purpose of this study was to evaluate the potential of voclosporin (VOS) in preventing goblet cell (GC) loss and modulating interferon-gamma (IFN-gamma) producing CD4+ T cells in the mouse desiccating stress (DS) dry eye model.	voclosporin	70-81	interferon gamma	Mus musculus	157-166
32721249-1	2020	Objective: The purpose of this study was to evaluate the potential of voclosporin (VOS) in preventing goblet cell (GC) loss and modulating interferon-gamma (IFN-gamma) producing CD4+ T cells in the mouse desiccating stress (DS) dry eye model.	voclosporin	70-81	CD4 antigen	Mus musculus	178-181
32894758-0	2020	Differential effects of voclosporin and tacrolimus on insulin secretion from human islets.	voclosporin	24-35	insulin	Homo sapiens	54-61